These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 35076721)

  • 1. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.
    Müller F; Kraus E; Holze F; Becker A; Ley L; Schmid Y; Vizeli P; Liechti ME; Borgwardt S
    Psychopharmacology (Berl); 2022 Jun; 239(6):1933-1943. PubMed ID: 35076721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
    Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hallucinogen-induced psychological disorders].
    Hermle L; Kovar KA; Hewer W; Ruchsow M
    Fortschr Neurol Psychiatr; 2008 Jun; 76(6):334-42. PubMed ID: 18512184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach.
    Lerner AG; Gelkopf M; Skladman I; Oyffe I; Finkel B; Sigal M; Weizman A
    Isr J Psychiatry Relat Sci; 2002; 39(2):92-9. PubMed ID: 12227234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety pharmacology of acute LSD administration in healthy subjects.
    Holze F; Caluori TV; Vizeli P; Liechti ME
    Psychopharmacology (Berl); 2022 Jun; 239(6):1893-1905. PubMed ID: 34515824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.
    Orsolini L; Papanti GD; De Berardis D; Guirguis A; Corkery JM; Schifano F
    Front Psychiatry; 2017; 8():240. PubMed ID: 29209235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinogen persisting perception disorder: what do we know after 50 years?
    Halpern JH; Pope HG
    Drug Alcohol Depend; 2003 Mar; 69(2):109-19. PubMed ID: 12609692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD.
    Halpern JH; Lerner AG; Passie T
    Curr Top Behav Neurosci; 2018; 36():333-360. PubMed ID: 27822679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
    Griffiths RR; Richards WA; McCann U; Jesse R
    Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features.
    Lerner AG; Gelkopf M; Skladman I; Rudinski D; Nachshon H; Bleich A
    Int Clin Psychopharmacol; 2003 Mar; 18(2):101-5. PubMed ID: 12598822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LSD Flashbacks - The Appearance of New Visual Imagery Not Experienced During Initial Intoxication: Two Case Reports.
    G Lerner A; Goodman C; Rudinski D; Lev-Ran S
    Isr J Psychiatry Relat Sci; 2014; 51(4):307-9. PubMed ID: 25841230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.
    Christensen JA; Fipps DC; Bostwick JM
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):300-304. PubMed ID: 36048112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flashbacks and HPPD: A Clinical-oriented Concise Review.
    G Lerner A; Rudinski D; Bor O; Goodman C
    Isr J Psychiatry Relat Sci; 2014; 51(4):296-301. PubMed ID: 25841228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.
    Zeifman RJ; Kettner H; Pagni BA; Mallard A; Roberts DE; Erritzoe D; Ross S; Carhart-Harris RL
    Sci Rep; 2023 Aug; 13(1):13645. PubMed ID: 37608057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
    Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
    Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.